A

Amgen

Makes biotech medicines for serious illnesses

Principal Information Systems Architect

Full-Time
$144.4k - $195.4k+ Annual bonus + Stock-based long-term incentives
Expert
Bachelor's, Master's, PhD, Associate's
Remote in USA
RemoteRemote role; may require travel up to 15%.
CybersecuritySecurity Engineering & Architecture
H1B Sponsorship Available

About the job

Requirements
  • Doctorate degree and 2 years of Information Systems and/or Computer Science experience, or master’s degree and 4 years of such experience, or bachelor’s degree and 6 years, or associate’s degree and 10 years, or high school diploma or GED and 12 years.
  • Knowledge of Web Access Management and single sign-on technologies, including Entra ID, Okta, Azure, Ping Federate, SAML, OAuth, and OpenID Connect.
  • Knowledge of Microsoft Active Directory, including AD LDS and Azure AD.
  • Knowledge of LDAP directories and Public Key Infrastructure.
  • Comprehensive experience with Amazon Web Services and/or Microsoft Azure, and understanding of Identity and Access Management.
  • Working knowledge of networking concepts and protocols, including LAN, WAN, SSL, firewall, load balancer, and DMZ configurations.
  • Knowledge of identity and access and role management applications, including IBM ISIM, IBM IGI, SailPoint IdentityIQ, Microsoft Identity Manager, Lieberman RED Identity Manager, Azure, and Microsoft B2B solutions.
  • Experience designing or operating enterprise secrets-management solutions such as HashiCorp Vault, AWS Secrets Manager, or Azure Key Vault.
  • Experience managing non-human identities and credentials, including service accounts, service principals, API keys, tokens, certificates, and application and automation secrets.
  • Knowledge of workload identity, federation, short-lived credentials, automated secret discovery and rotation, and secure integration with CI/CD pipelines and cloud platforms.
  • Ability to define and implement secrets-management governance, including ownership, access controls, auditability, rotation, expiration, and incident response.
  • Experience with mobile device authentication and management.
  • Scripting skills such as PowerShell, Perl, or VBScript.
  • Ability to work effectively with global teams and manage multiple priorities.
  • One or more relevant certifications, including Certified Information Security Manager, CompTIA Security+, Certified Information Systems Security Professional, or SANS Global Information Assurance Certifications.
Responsibilities
  • Provide technical and governance oversight to all Identity Management projects; serve as technical architect in their analysis, design, and implementation; ensure successful delivery and solution security and integrity; and advise project teams on architectural standards and information security methodologies.
  • Lead the architecture and integration of enterprise secrets-management and non-human identity capabilities, establishing patterns for service accounts, application identities, API keys, tokens, certificates, and other secrets across cloud, data, and enterprise platforms, and partnering with platform and application teams to meet security standards and integrate with enterprise IAM.
  • Provide leadership and day-to-day operational management, participate in troubleshooting, manage critical issues, guide disaster recovery exercises, plan continuous process improvement, and coordinate budgets for staff and other organizational functions and services.
  • Manage and implement technologies and processes for the assigned Cybersecurity and Digital Trust capability, including issue identification and resolution, tool integration, documentation, gap assessment and resolution, and continuous improvement.
  • Develop or participate in developing business cases and presentations on information security technologies.
  • Advise project teams, application owners, and other Information Security teams on information security controls.
  • Support incident response for security incidents, including participating in mock security incident exercises.
  • Perform security design consulting in support of projects, including participating in security architecture reviews as needed.
  • Provide mentorship and training in areas of expertise to Cybersecurity and Digital Trust and Amgen teams.
  • Participate in departmental legal, regulatory, and contractual compliance activities as needed.
  • Handle after-hours responsibilities and travel up to 15% as required.
Desired Qualifications
  • Military experience.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

PR Newswire
Oct 26th, 2026
Amgen appoints former Yum! Brands CEO David Gibbs to its board

Amgen has appointed David W. Gibbs to its board of directors, effective immediately. He will serve on the Audit Committee and the Compensation and Management Development Committee. Gibbs recently retired as president and chief executive officer of Yum! Brands, owner of Taco Bell and Kentucky Fried Chicken. As chief executive from 2020 to 2025, he led its digital transformation and expanded it to nearly 61,000 locations. He has sat on the board of Under Armour since 2021 and PepsiCo since 2026. "His experience creating direct relationships with customers will help inform how we prepare for future launches," said Robert A. Bradway, Amgen's chairman and chief executive officer. The board now has 13 directors, 12 of them independent.

Yahoo Finance
Oct 26th, 2026
ESMO 2026: Moderna vaccine debate, Roche's $3.6B KRAS bet and Amgen's lung cancer data

Three cancer drug trials drew attention at the European Society for Medical Oncology (ESMO) meeting, with investors and analysts weighing the results. Moderna and Merck's vaccine intismeran autogene cut the relative risk of melanoma recurrence or death by 42% in a Phase 3 trial. Moderna's shares have still fallen by double digits since the results leaked early, as investors question its valuation and the vaccine's manufacturing and commercial potential. Roche's divarasib reduced the risk of death or disease progression by 42% in KRAS G12C lung cancer, beating Krazati and Lumakras. Patients lived a median of about 18 months, versus a year. Roche raised its peak sales forecast from 3.6 billion Swiss francs to 3 billion. Amgen's Imdelltra, combined with Imfinzi, cut the risk of death by 58% in small cell lung cancer. Median survival was 21.1 months, against 12.7 months for Imfinzi alone.

Yahoo Finance
Oct 25th, 2026
Amgen vs Gilead: Which biotech dividend stock is the better buy, with yields of 2.2% and 2.1%?

Amgen and Gilead Sciences, two of the few big biotech companies that pay dividends, suit different kinds of income investors, according to a comparison by The Motley Fool's Keith Speights. Amgen offers a forward dividend yield above 2.2%, against slightly below 2.1% for Gilead. Gilead has the lower payout ratio, at 43.5% versus 60.9%, and the cheaper valuation: 15.6 times forward earnings against 16.7. Amgen's product sales grew 9% year over year in its latest quarter, against 8% for Gilead. It has 17 drugs on track to be blockbusters this year, versus eight for Gilead, and 29 late-stage programs. Speights favours Amgen for yield and growth, and Gilead for safety and value.

Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 22nd, 2026
Eli Lilly vs Amgen: $65.2B revenue and 45% growth against a cheaper stock for 2026

Eli Lilly is growing far faster than Amgen, but investors pay a steep premium for it. The article's author favours Lilly for long-term investors in 2026. Lilly's FY 2025 revenue rose 45% to about $65.2 billion, with net income of $20.6 billion and a 32% net margin. Amgen's revenue grew about 10% to $36.7 billion, with net income of $7.7 billion and a 21% margin. Lilly trades at a forward P/E of 38.3x against Amgen's 19.4x. Its debt-to-equity ratio is about 1.6x, compared with nearly 6.3x for Amgen. Lilly's growth rests on its GLP-1 drugs Zepbound and Mounjaro. The article projects 2026 revenue of $88.7 billion, against about $37.8 billion for Amgen.